MedTrace Logo

Granulocyte-colony Stimulating Factor for Stem Cells Therapy for Acute Ischemic Stroke

NCT00901381 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-01-07

No results posted yet for this study

Summary

The aim of the study is to investigate treatment with Leukostim (Filgrastim; granulocyte-colony stimulating factor; G-CSF) for acute ischemic stroke.

Conditions

Interventions

DRUG

Filgrastim

10 µg/kg subcutaneously once daily x 5 days

Sponsors & Collaborators

  • Institute of Medical Cells Technologies

    collaborator UNKNOWN

  • City Hospital No 40, Saint Petersburg, Russia

    collaborator OTHER

  • Clinical Institute of the Brain, Russia

    lead OTHER

Principal Investigators

  • Andrey A Belkin, MD, PhD. · Clinical Institute of the Brain, Russia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00901381 on ClinicalTrials.gov